SuperworthX4 Pharmaceuticals price to sales ratio XFOR
Market value divided by revenue over the last twelve months, since 2021.
- Today, Oct 23, 2026
- 20.3×
- 6-year median
- 10.0×
- Against its 6-year history
- 68th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.3× to 53.0×
- Peer median
- 3.6×
X4 Pharmaceuticals' price to sales ratio is 20.3× as of Oct 23, 2026.
That is above its 6-year median of 10.0×, higher than on 68% of days in the last 6 years.
Over that time it ranged from 0.3× in Jul 2025 to 53.0× in Mar 2021.
The median for 4 biotech stocks of a similar size is 3.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 20.3× | 8.1× | 46.4× |
| 2025 | 11.6× | 0.3× | 11.6× |
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | n/m a value too high to mean anything | ||
| 2021 | 48.6× | 48.6× | 53.0× |
Against its peers
Companies in Biotechnology nearest X4 Pharmaceuticals' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| XFORX4 Pharmaceuticals | 20.3× |
| PLXProtalix BioTherapeutics | 2.5× |
| MGTXMeiraGTx | 2.2× |
| VCELVericel | 7.1× |
| ADMAAdma Biologics | 4.7× |
| Peer median | 3.6× |
Where X4 Pharmaceuticals ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on X4 Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.